Castle Biosciences stock reports 99.6% melanoma survival data
Published on 10/05/2026 at 13:01 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Castle Biosciences stock (ISIN US14843C1053) was last at USD 35.56 on Nasdaq on October 2, 2026, with a 0.87 percent gain for the session. The company presented new DecisionDx-Melanoma findings at the European Academy of Dermatology and Venereology Congress, according to PR Newswire on September 30, 2026.
Melanoma data sharpen the story
The late-breaking study enrolled 2,799 patients at 29 U.S. centers. Among 676 patients who underwent sentinel lymph node biopsy, the observed positivity rate was 4.4 percent for low-risk results, compared with 22.8 percent for high-risk results, according to PR Newswire.
The most investor-relevant result was the five-year recurrence-free survival rate of 99.6 percent among 565 eligible patients with low-risk results who did not undergo the biopsy. A separate analysis of 687 transected melanomas showed five-year recurrence-free survival of 93.2 percent for Class 1A results versus 64.1 percent for Class 2B results, giving the company a clinical-data angle beyond routine staging.
Quarterly beat supports expansion
Castle Biosciences also enters the data discussion with a recent operating beat. For the second quarter ended June 30, 2026, revenue reached USD 103.5 million versus a USD 86.4 million consensus estimate, while adjusted loss was USD 0.07 per share versus an expected USD 0.40 loss, according to Investing.com.
The comparison matters because the company is funding a broader diagnostics portfolio while expanding beyond dermatology. The latest release also describes AdvanceAD-Tx, a 487-gene test for atopic dermatitis, alongside DecisionDx-Melanoma and the companys other molecular assays.
Analyst target stays above the quote
Lake Street analyst Thomas Flaten maintained a Buy rating and a USD 57.00 price target in a report published October 1, 2026, according to Markets Insider. The target lies 60.3 percent above the October 2 price, while the same report cited a Strong Buy consensus and an average target of USD 45.40.
Stock remains below yearly high
CSTL was last at USD 35.56 on Nasdaq on October 2, 2026 at 4:00 p.m. ET, with a session high of USD 35.92, a low of USD 34.76 and volume of 167,719 shares. Its 52-week range was USD 17.72 to USD 44.28, leaving the quote 19.7 percent below the high.
Castle Biosciences stock facts
- Company: Castle Biosciences, Inc.
- ISIN: US14843C1053
- Ticker: CSTL
- Trading venue: Nasdaq
- Price (as of October 2, 2026, 4:00 p.m. ET): USD 35.56
- Market capitalization: USD 1.1 billion (as of October 2, 2026)
- 52-week range: USD 17.72-44.28 (as of October 2, 2026)
- Sector / Industry: Healthcare / Medical Equipment, Supplies and Distribution
